Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:AMRNNASDAQ:BMEANASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$10.50+4.9%$9.11$4.88▼$19.58$227.81MN/A112,131 shs22,053 shsAMRNAmarin$11.11+1.1%$9.79$7.08▼$18.00$230.08M0.6676,229 shs30,664 shsBMEABiomea Fusion$1.48+2.1%$1.95$1.36▼$13.07$55.61M-0.07909,397 shs475,892 shsMNPRMonopar Therapeutics$35.45+0.0%$37.93$1.72▼$54.30$216.78M1.11359,452 shs14,864 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-9.98%+10.12%+30.68%-28.60%+1,000,999,900.00%AMRNAmarin+0.09%+4.47%+5.07%-6.72%-36.97%BMEABiomea Fusion0.00%+1.40%-25.64%-58.09%-87.39%MNPRMonopar Therapeutics-0.34%-10.39%-17.50%-11.95%+1,053.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.3627 of 5 stars1.04.00.00.01.50.00.0BMEABiomea Fusion2.747 of 5 stars3.50.00.00.03.43.31.3MNPRMonopar Therapeutics2.8904 of 5 stars3.45.00.00.02.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25197.62% UpsideAMRNAmarin 2.00Hold$7.00-36.99% DownsideBMEABiomea Fusion 3.08Buy$22.601,427.03% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3356.09% UpsideCurrent Analyst Ratings BreakdownLatest BMEA, AARD, AMRN, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.004/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AAMRNAmarin$214.11M1.07N/AN/A$1.35 per share8.23BMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)BMEABiomea Fusion-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)Latest BMEA, AARD, AMRN, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AAMRNAmarinN/A3.232.11BMEABiomea FusionN/A3.393.39MNPRMonopar TherapeuticsN/A5.415.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AAMRNAmarin22.25%BMEABiomea Fusion96.72%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AAMRNAmarin3.30%BMEABiomea Fusion27.57%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AAMRNAmarin36020.71 million402.62 millionOptionableBMEABiomea Fusion5037.57 million26.25 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableBMEA, AARD, AMRN, and MNPR HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 23 at 4:36 AM | marketbeat.comJanus Henderson Group PLC Invests $23.44 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 18, 2025 | marketbeat.comResearch Analysts Set Expectations for MNPR Q2 EarningsMay 18, 2025 | americanbankingnews.comMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 14, 2025 | manilatimes.netMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 13, 2025 | globenewswire.comMonopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025May 8, 2025 | nasdaq.comMonopar Presents ALXN1840 Late-Breaker Data at EASL 2025May 7, 2025 | globenewswire.comGeode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR)May 4, 2025 | marketbeat.comRA Capital Management L.P. Invests $11.25 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)May 3, 2025 | marketbeat.comMonopar Therapeutics (MNPR) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comWhy Monopar Therapeutics Inc. (MNPR) is Surging in 2025April 30, 2025 | insidermonkey.comAdage Capital Partners GP L.L.C. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)April 30, 2025 | marketbeat.comMonopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025April 29, 2025 | globenewswire.comPiper Sandler Remains a Buy on Monopar Therapeutics Inc (MNPR)April 14, 2025 | markets.businessinsider.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 9.91%April 10, 2025 | aaii.comWhy Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 13.27%April 5, 2025 | aaii.comTactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) StockApril 5, 2025 | insidertrades.comMonopar Therapeutics downgraded to Hold from Buy at JonesResearchApril 2, 2025 | markets.businessinsider.comJones Trading Downgrades Monopar Therapeutics (MNPR)April 2, 2025 | msn.comJonesTrading downgrades Monopar Therapeutics Inc (MNPR) to a HoldApril 2, 2025 | markets.businessinsider.comWe Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business GrowthApril 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMEA, AARD, AMRN, and MNPR Company DescriptionsAardvark Therapeutics NASDAQ:AARD$10.50 +0.49 (+4.90%) As of 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Amarin NASDAQ:AMRN$11.11 +0.12 (+1.09%) Closing price 04:00 PM EasternExtended Trading$11.18 +0.07 (+0.63%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Biomea Fusion NASDAQ:BMEA$1.48 +0.03 (+2.07%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.02 (-1.35%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Monopar Therapeutics NASDAQ:MNPR$35.45 +0.01 (+0.03%) Closing price 04:00 PM EasternExtended Trading$35.45 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
